Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity‑Care ACA Drug Formulary Coverage | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCommunity-CarePolicy N/A

    CommunityCare ACA Prescription Drug Formulary (partial) - Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes CommunityCare ACA prescription drug list structure, member obligations to use network pharmacies, formulary rules (prior authorization, step therapy, quantity limits), tiers and copay structure, and examples affecting CommunityCare ACA members and their prescribing providers/pharmacies.

    Policy Summary
    PayerCommunity-Care
    PolicyCommunityCare ACA Prescription Drug Formulary (partial) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when a listed drug indicates PA, and ensure prescriptions are filled at an in‑network CommunityCare pharmacy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    requirednetwork pharmacies required
    PA/ST/QLUM types used
    severalhigh-strength PA flagged
    multiplequantity limits examples
    72/24exception timeframes

    Coverage Criteria and Formulary Rules

    General formulary coverage

    Covered when ALL of the following are met:

    Formulary coverage general criteria: (1) Drug is listed on the CommunityCare ACA drug list; (2) Drug is medically necessary; (3) Prescription is filled at a CommunityCare ACA network pharmacy; (4) Other plan rules (e.g., prior authorization, quantity limits, step therapy) are followed

    From formulary overview

    Formulary coverage summary (partial)

    Coverage is defined by formulary tier and, where indicated, prior authorization and quantity limits.

    Formulary entries: Individual drugs are assigned a formulary tier and may require prior authorization (PA), step therapy (ST), and/or quantity limits (QL) as shown on the drug list; coverage is provided when those requirements are met.see product-level QL entries

    No patient-specific clinical eligibility criteria provided in this excerpt

    Policy Summary
    PayerCommunity-Care
    PolicyCommunityCare ACA Prescription Drug Formulary (partial) - Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and submit supporting documentation when a listed drug indicates PA, and ensure prescriptions are filled at an in‑network CommunityCare pharmacy.
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesDrug Entries, Codes, and Quantity ExamplesAuthorization, Documentation, and Denial RisksInitial Therapy and Start-of-Treatment RulesStep Therapy Requirements and Affected ProductsQuantity Limits by ProductWhere Drugs Must Be Dispensed / AdministeredBackground and Definitions

    Formulary coverage with utilization controls

    Coverage is reported as tier placement with utilization controls; drugs are covered subject to the listed PA/ST/QL conditions.

    Migraine specialty examples: QULIPTA (atogepant), UBRELVY (ubrogepant), AIMOVIG (erenumab), EMGALITY (galcanezumab) are placed on formulary with ST and QL and may have PA applicability (PA**); EMGALITY allows a 2‑injection loading dose for the initial fill.QULIPTA QL 30 tabs/30 days; UBRELVY QL 16 tabs/30 days; AIMOVIG QL 1 injection/30 days; EMGALITY QL 1 injection/30 days (loading: 2 injections in 30 days)

    chunks 145,147

    Specialty/oncology examples: Selected antineoplastic agents (e.g., dasatinib, everolimus, imatinib, cabozantinib kits) are Tier 4/5 and require PA and have QL as specified on their lines.see individual product QL entries (e.g., dasatinib 20mg QL 90 tabs/30 days; COMETRIQ kits QL 1 kit/28 days)

    chunks 72,74,80

    Formulary coverage with PA/ST/QL

    Covered when listed on formulary subject to specified utilization management controls

    Endocrine/antidiabetic examples: Drugs in the endocrine section (e.g., JANUMET, JANUVIA, MOUNJARO, OZEMPIC, TRULICITY) are covered on the indicated tier when requirements (ST, PA, QL) are satisfied.product-level QL (e.g., MOUNJARO QL 4 pens/28 days; OZEMPIC QL 3 mL/28 days; TRULICITY QL 4 pens/28 days)

    chunks 162-164

    Contraceptives / LARC

    Coverage and limits for contraceptives and long-acting reversible contraception

    Contraceptives and LARC: Many contraceptive products are Tier 0 and covered; selected intrauterine devices (IUDs) and implants (KYLEENA, LILETTA, MIRENA, NEXPLANON, SKYLA, etc.) have a quantity limit of 1 replacement every 300 days.1 every 300 days

    Applies to named IUDs/implants per formulary lines

    Diabetic supplies and pumps

    Coverage and limits for diabetic supplies and insulin delivery systems

    Glucose monitoring and insulin delivery: Blood glucose test strips (Accu-Chek/OneTouch) are covered with a QL of 150 test strips every 30 days; CGM sensors (Dexcom G6/G7) have a QL of 3 sensors every 30 days. Insulin pumps and associated refill kits (Omnipod, V‑GO, TWIIST) are listed (Tier 2) with coverage per product line.150 strips/30 days; 3 sensors/30 days

    chunks 188,190,193,194,196

    Glucocorticoids / Endometriosis

    Glucocorticoids and endometriosis agents

    Agents requiring PA or QL: Some glucocorticoids and endometriosis agents are subject to PA and/or QL (examples: deflazacort susp/tab formulations list PA and QL; SYNAREL (nafarelin) is marked PA).varies by product

    chunks 196-199

    Per-product coverage and requirements

    Coverage and requirement snippets from listed products in this excerpt.

    VIBERZI (eluxadoline): VIBERZI tabs 75mg and 100mg are Tier 2 and require prior authorization (PA).

    chunk 218

    Bowel‑prep age‑based coverage: Multiple bowel‑preparation products (e.g., CLENPIQ, PEG‑PREP KIT, PLENVU, SUTAB) are Tier 0 with a $0 copay for members aged 45–75; coverage differs for members outside that age band as noted per product line.age 45–75

    chunks 220-223

    PPIs and annual QL: Proton pump inhibitors (e.g., esomeprazole) have annual quantity limits (example: esomeprazole QL 90 caps every 365 days).90 caps/365 days

    chunk 223

    Hematologic specialty agents: Selected hematologic growth factors and specialty agents (e.g., ARANESP, FYLNETRA, pegfilgrastim products) require PA and may have QL (e.g., FYLNETRA QL 2 syringes/28 days).varies by product

    chunks 231,235

    VOWST and SUCRAID: VOWST (fecal microbiota spores) and SUCRAID (sacrosidase) are Tiered products with PA and QL (e.g., VOWST QL 12 caps/30 days; SUCRAID QL 354 mL/30 days).12 caps/30 days; 354 mL/30 days

    chunks 222,235

    Formulary coverage rules (by product)

    Coverage determined by product tier and explicit Requirements/Limits where present

    Vaccine age‑based coverage: Selected vaccines have $0 copay for specified age groups and are otherwise not covered when age criteria are not met (examples: BEYFORTUS $0 copay age ≤18; AREXVY $0 copay age ≥19).age specific per product

    chunk 254

    Folic acid OTC eligibility and QL: Folic acid 400/800 mcg OTC is $0 copay for members 55 and younger capable of pregnancy and has a QL of 100 caps/tabs every 30 days; otherwise not covered as specified.age ≤55 and pregnancy‑capable; QL 100 caps/30 days

    chunk 266

    Prescriptions are covered only when dispensed at a CommunityCare in‑network pharmacy. There is no coverage for prescription medications obtained from out‑of‑network pharmacies within the state of Oklahoma.

    Aspirin (over‑the‑counter formulations listed as low‑dose/EC) is covered at a $0 copay for members identified as being at risk for preeclampsia. For members who do not meet that risk criterion, these OTC aspirin products are not covered under the formulary entry shown.

    Certain medications designated as High Risk Medications require prior authorization for members age 70 and older. Nitrofurantoin products (suspensions and capsules) are explicitly listed with Requirements/Limits = PA and the high‑risk age‑based PA requirement in the formulary extract.

    Exceptions to formulary preferences or utilization controls will generally only be approved when a prescriber documents that a preferred drug would be less effective for the member or would cause adverse medical effects. The prescriber must submit supporting clinical justification when requesting an exception, and expedited requests require clinician rationale for faster review.

    The excerpt does not include standalone, formalized statements applying a blanket 'not medically necessary' label to specific drugs. Instead, coverage decisions are driven by per‑product tier placement and utilization management annotations (e.g., PA, ST, QL); where a product is marked 'otherwise not covered' that determination is applied at the product/age or requirement level rather than as a general NMN statement in this extract.

    Several product lines include explicit language that they are 'otherwise not covered' when age‑based criteria are not met (for example, certain bowel‑prep products specify $0 copay for members age 45 through 75; otherwise not covered, and some vaccines list age bands with '$0 copay, otherwise not covered'). These per‑product phrases function as the formulary's practical NMN‑style rules for members outside the specified age ranges in this excerpt.

    Drug Entries, Codes, and Quantity Examples

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Many drugs listed on the CommunityCare ACA Drug List require Prior Authorization (PA), Step Therapy (ST), and/or Quantity Limits (QL). Providers must obtain PA where indicated before dispensing; failure to secure required PA, ST, or QL approval can result in claim denial or member liability. Follow product‑level requirements shown in the Requirements/Limits column (including PA, PA**, ST, QL, initial short‑term limits, loading dose allowances, and age‑based restrictions).

    • Prior authorization required for high‑strength opioid formulations and certain branded products (PA flag shown next to product; example: high‑strength fentanyl patches, high‑strength oral opioids).
    • PA required for many oncology, hematologic, and specialty agents; product entries often include PA plus specific QL (e.g., VENCLEXTA, KADCYLA, KEYTRUDA, REVLIMID, PADCEV, POMALYST, MEKINIST, etc.).
    • PA and QL commonly apply to immunologic and other specialty biologics, self‑administered and physician‑administered (examples: many kinase inhibitors, somatostatin analogs, octreotide, lanreotide, pegvisomant, select MS, PAH, and pulmonary hypertension agents).
    • PA required for select hepatitis B/C and high‑tier antiviral regimens (examples: EPCLUSA, HARVONI, SOVALDI, VOSEVI, VOSEVI, sofosbuvir products — many require ST + PA + QL where noted).
    • Certain injectable antiretroviral kits and long‑acting HIV regimens require PA and have kit‑level QL and loading‑dose rules (examples: CABENUVA kit entries with PA, QL, and an allowed 30‑day loading dose kit).
    • Some Parkinson disease products require PA and QL (example: INBRIJA caps — PA with QL 300 caps/30 days; ONGENTYS = PA).
    • Specific products of note with PA or PA+QL: VIBERZI; selected hematologic agents (venetoclax/VENCLEXTA start pack and strength‑specific QL); deflazacort formulations noted with PA and QL in the Requirements/Limits column where listed.
    • Age‑based restrictions and PA triggers: high‑risk medications (for example, nitrofurantoin formulations) require PA for members age 70 and older; other age or indication limits appear at the product level.
    • Step therapy applies for many analgesics and other selected agents — ST entries on the chart indicate the member must try preferred agents first; examples include many opioid formulations and select sofosbuvir products.
    • Quantity limits and initial short‑term limits are documented per product (examples: many opioid liquid/solid formulations are subject to initial 7‑day limits; lozenge, patch, vial, kit, and ampule QLs are specified per product).
    • Documentation required for PA and exceptions: prescriber must submit supporting clinical statement and dosing documentation (including loading dose when applicable), dosing interval, and justification for QL/ST exceptions; expedited exception requests require clinician justification for faster review.
    • Operational notes: IV ceftriaxone and other injectables may have initial course limits; physician‑administered immunologic agents often require PA/ST/QL and may have different step or prior authorization rules than self‑administered biologics.
    • Triggers for denial: claims may be denied if PA/ST/QL requirements are not met, if prescriptions are not filled at a CommunityCare ACA network pharmacy when required, or if necessary documentation (including dosing interval, loading dose, or prescriber justification) is not provided.
    • When requesting exceptions: expect to support QL and initial limits with clinical documentation; decisions are made within 72 hours once necessary information is received, or within 24 hours for approved expedited requests.
    • Providers should consult the Requirements/Limits column for each product for exact PA, ST, QL, loading dose, kit frequency, and age‑based rules — this is the authoritative source for product‑level requirements.
    Denial Risk

    Denial Risks if Authorization or Criteria Not Met

    Failure to obtain required authorization, to satisfy step therapy, or to comply with quantity limits may result in denial of coverage or member financial responsibility. Claims for drugs that list PA, ST+PA, or QL in the Requirements/Limits column are subject to retrospective or prospective denial if criteria are not met.

    • Denial triggers include: no prior authorization on file when PA is required; step therapy requirements not completed; quantity limits exceeded; prescriptions filled outside the CommunityCare ACA network when plan rules require in‑network pharmacy; missing clinical documentation (including dosing interval, loading dose, or prescriber statement).
    • Some PA/ST requirements are strength‑specific — higher strengths may require PA even when lower strengths do not. If high‑strength flags appear (e.g., high‑strength fentanyl, hydrocodone, morphine, oxymorphone, tramadol, etc.), obtain PA before dispensing to avoid denial.
    • PA/ST may apply differently to physician‑administered vs self‑administered products; ensure the correct route and billing pathway are used and that PA documentation reflects the administration setting.
    Documentation Required

    Documentation Requirements for PA and Exceptions

    Providers must submit clinical justification and supporting documentation when requesting PA or exceptions. For standard PA reviews, provide sufficient medical records, indication, prior medications tried (for ST), dosing regimen, and rationale for requested quantity or frequency. Expedited requests require explicit clinician justification of harm if delayed.

    • Exception request documentation: prescriber statement supporting the exception; prior treatment history (to meet ST requirements); rationale for medical necessity when requesting overrides to QL or ST.
    • Support for QL and initial limits: document anticipated duration of therapy, planned dosing interval, and any loading doses. If a loading dose is expected (e.g., CABENUVA, certain biologics), include the intended loading kit and timing in the request.
    • General PA documentation: include diagnosis, prior therapies and responses, contraindications or intolerance to preferred agents, weight/age when relevant (age‑based vaccine or high‑risk med rules), and anticipated quantity or number of kits/vials per period.
    • PA/QL documentation for self‑administered biologics and physician‑administered immunologics: include dosing schedule, injection frequency, number of pens/vials per fill, and site of administration if relevant. Many biologics also require QL supporting documentation.
    • Folic acid and other supportive QLs: confirm eligibility or concurrent therapy where QLs are tied to specific indications. For example, folic acid QLs may be linked to disease‑specific eligibility; provide supporting diagnoses.
    • IV ceftriaxone and other limited‑course injectables: document the intended initial course length and indicate if subsequent courses are planned; initial course limits are enforced unless additional clinical justification is supplied.
    Step Therapy

    Step Therapy Requirements

    Step therapy is required for many drug classes. When ST is listed, the member must have trials of preferred agents (documented) before a non‑preferred agent will be approved. Some physician‑administered agents also have step requirements.

    • Step therapy common across many analgesics and other classes — examples include numerous opioid formulations that show ST plus initial 7‑day limits.
    • Step therapy applies to select sofosbuvir/antiviral products and certain endocrine and antidiabetic combinations (entries showing ST; PA** indicates a combined ST+PA workflow).
    • Where step therapy is present, providers should submit prior treatment history and evidence of failure, intolerance, or contraindication to preferred agents when requesting exceptions.

    Initial Therapy and Start-of-Treatment Rules

    Initial therapy rules

    Utilization management for initiating therapy

    Initial therapy general requirements: Preferred generics are preferred when available; step therapy may require trial of a preferred agent before coverage of a non‑preferred agent. Prior authorization and quantity limits may apply at initiation per product lines.

    chunk 6

    Initial therapy limits

    Many immediate‑release and other analgesic products are subject to initial short‑term limits.

    Initial short‑term limits for analgesics: Multiple oral and liquid opioid/analgesic formulations are noted as 'Subject to initial 7‑day limit' where shown alongside quantity limits; prescribers should expect initial short fills for new therapy starts.initial 7‑day limit

    see analgesics section lines (chunks 18–29)

    Initial fill provisions

    Initial fill allowances noted for select products.

    EMGALITY loading dose: EMGALITY (galcanezumab) allows a loading dose of 2 injections in 30 days for the initial fill; thereafter QL applies (1 injection every 30 days or as listed).2 injections/30 days initial; then 1 injection/30 days

    chunk 145

    Initial therapy rules

    Initial placement on therapy is subject to tier and utilization management controls

    Initial coverage subject to UM: Drugs are covered on the indicated tier for initiation but may require step therapy, prior authorization, and/or quantity limits as specified on the drug list; prescribers must meet those requirements for coverage of initial therapy.see product‑level QL/PA entries

    chunks 163-164

    PPI coverage

    PPI initial coverage notes in excerpt

    PPI annual limit: Proton pump inhibitors such as esomeprazole are listed with an annual quantity limit (example: esomeprazole QL 90 capsules every 365 days).90 caps/365 days

    chunk 223

    Step Therapy Requirements and Affected Products

    RequirementSummary
    Trial of preferred agentMembers must try a preferred agent first when step therapy (ST) is indicated; coverage for the requested alternative is contingent on meeting the step therapy requirement.
    Failure criteriaDocumentation that the preferred agent was ineffective or caused adverse effects may be required to meet the exception to ST.
    ScopeDetails
    Products/classesMany analgesic products and strengths are listed with 'ST' in Requirements/Limits (examples include acetaminophen/codeine formulations, codeine sulfate, endocet, fentanyl patches/lozenges, hydrocodone and oxycodone products, tramadol, morphine, NUCYNTA, BELBUCA), indicating step therapy applies.
    Prescriber actionPrescribers should follow the step therapy pathways shown on each product line; claims may be denied if ST requirements are not met.
    ProductST/PA/QL Notes
    CABENUVA SUS 400-600 kitRequirements/Limits = PA, QL (1 kit every 30 days).
    CABENUVA SUS 600-900 kitRequirements/Limits = PA, QL (1 kit every 60 days); loading dose allowance: 1 kit in 30 days allowed for initial fill.
    ProductStep Therapy Note
    SOVALDI PACK 200mg; SOVALDI TABS 200mg/400mgRequirements/Limits include ST, PA, QL (28–56 pellets or tabs per 28 days depending on pack), indicating step therapy is required for some sofosbuvir formulations.
    ExampleST/PA/QL Details
    ranolazineListed with Requirements/Limits = ST; PA** — completion of step therapy is required prior to coverage and prior authorization applies as noted.
    TRINTELLIX (vortioxetine)Requirements/Limits = ST; PA** listed on the product line, indicating step therapy must be completed before coverage and PA applies.
    Products (examples)ST Indication
    VRAYLAR (cariprazine)Requirements/Limits include ST; PA** for certain presentations — step therapy indicated on product line.
    QULIPTA; UBRELVY; AIMOVIG; EMGALITYEach listed with 'ST' in Requirements/Limits (EMGALITY and others also show QL and PA**); exact step details are not enumerated within these lines in the excerpt.
    Products / ClassesST Details
    QULIPTA; UBRELVY; AIMOVIG; EMGALITYRequirements/Limits = ST (and QL/PA** where shown) — step therapy is required before coverage as listed on each product line.
    DPP-4 inhibitors and sitagliptin/metformin combinations (e.g., JANUMET, JANUMET XR)Product lines indicate 'ST' (and PA**), showing step therapy is required for these agents where noted.
    Class / ProductsST Note
    Combination and branded antidiabetics (examples)Products such as JANUMET, SOLIQUA, XULTOPHY, SYNJARDY, GLYXAMBI are listed with 'ST' in Requirements/Limits, indicating step therapy is required prior to coverage of these agents.
    Physician‑administered productST/PA/QL
    ACTEMRA (tocilizumab) solutions and syringesRequirements/Limits = ST, PA, QL (varies by presentation: e.g., 20 vials/28 days for 80mg/4ml; 4 syringes/28 days for self‑administered); ST is listed as a requirement for some presentations.
    SIMPONI ARIA (golimumab) solutionRequirements/Limits = PA, QL (200 mg every 8 weeks); some physician‑administered agents include ST as a prerequisite per product entries.

    Quantity Limits by Product

    inv-144: diclofenac sodium (topical) gel 1% — 300g
    Productdiclofenac sodium (topical) gel 1%
    Quantity300 g every 30 days
    Formulary noteTier 1; listed as VOLTAREN ARTHRITIS PAIN GEL 1%
    inv-145: acetaminophen w/ codeine solution — 2700
    Productacetaminophen with codeine solution 120/12 mg per 5 mL
    Quantity2700 mL every 30 days
    RequirementStep therapy (ST) and QL; subject to initial 7‑day limit
    inv-146: various opioid tablets (examples: acetaminophen/codeine, endocet, codeine sulfate) — variable (examples: 42–360 tabs per 30 days); subject to initial 7-day limit
    Products (examples)acetaminophen/codeine tabs, endocet, codeine sulfate and other opioid tablets
    Quantity examplesRanges shown in listing (examples: 42–360 tabs per 30 days depending on product/strength)
    Initial supply ruleSubject to initial 7‑day limit
    inv-147: fentanyl pt72 patches (lower strength) — 10 patches
    Productfentanyl pt72 (selected lower strengths, e.g., 12, 25, 37.5 mcg/hr)
    Quantity limit10 patches every 30 days
    RequirementStep therapy indicated for some strengths; higher strengths require PA
    inv-148: acetaminophen w/ codeine soln 120-12 mg/5ml — 2700 mL
    Productacetaminophen with codeine solution 120/12 mg per 5 mL
    Quantity2700 mL every 30 days
    RequirementST and QL; subject to initial 7‑day limit
    inv-149: acetaminophen w/ codeine tab 300-15 mg — 400
    Productacetaminophen with codeine tab 300/15 mg
    Quantity400 tabs every 30 days
    RequirementST and QL; subject to initial 7‑day limit
    inv-150: codeine sulfate tabs 30mg — 42
    Productcodeine sulfate tabs 30 mg
    Quantity42 tabs every 30 days
    RequirementST and QL; subject to initial 7‑day limit
    inv-151: endocet tab 2.5-325 — 360
    ProductEndocet (oxycodone/acetaminophen) tab 2.5/325 mg
    Quantity360 tabs every 30 days (for listed strengths)
    RequirementST and QL; subject to initial 7‑day limit
    inv-152: fentanyl pt72 (selected strengths) — 10
    Productfentanyl pt72 (selected strengths)
    Quantity10 patches every 30 days
    RequirementST for lower strengths; high strengths require PA
    inv-153: NUCYNTA TABS 50mg — 120
    ProductNUCYNTA tablets 50 mg (tapentadol)
    Quantity120 tabs every 30 days
    RequirementST and QL; subject to initial 7‑day limit for certain formulations
    inv-154: ASPIRIN EC ADULT LOW DOSE — 100
    ProductAspirin EC adult low dose (81 mg)
    Quantity100 tabs every 30 days
    Coverage noteOTC; $0 copay for members at risk for preeclampsia, otherwise not covered
    inv-155: darunavir tabs 600mg — 60
    Productdarunavir tablets 600 mg
    Quantity60 tabs every 30 days
    RequirementQL noted in listing
    inv-156: BIKTARVY TAB — 30
    ProductBIKTARVY tablet (bictegravir-emtricitabine-tenofovir alafenamide)
    Quantity30 tabs every 30 days
    RequirementQL noted in listing
    inv-157: EPCLUSA TAB 200-50MG — 28
    ProductEPCLUSA tab 200/50 mg (sofosbuvir-velpatasvir)
    Quantity28 tabs/pellets every 28 days (pack-dependent)
    RequirementPA and QL as listed
    inv-160: ceftriaxone sodium soln (1gm,2gm,250mg,500mg) — 2 vials
    Productceftriaxone sodium solution (1 g, 2 g, 250 mg, 500 mg)
    Quantity2 vials every day
    Initial courseInitial limit allows up to a 14‑day course every 365 days
    inv-188: COMETRIQ kits (cabozantinib) — 1 kit
    ProductCOMETRIQ kits (cabozantinib)
    Quantity1 kit every 28 days
    RequirementPA and QL as listed
    inv-190: dasatinib tabs 20mg — 90 tabs
    Productdasatinib tablets 20 mg
    Quantity90 tabs every 30 days
    RequirementPA and QL indicated
    inv-192: LYNPARZA TABS — 120 tabs
    ProductLYNPARZA tablets (olaparib)
    Quantity120 tabs every 30 days
    RequirementPA and QL indicated
    inv-199: INBRIJA (levodopa) caps — 300 caps every 30 days
    ProductINBRIJA (levodopa) capsules
    Quantity300 caps every 30 days
    RequirementPA and QL noted for certain strengths (e.g., 42 mg) in listing
    inv-211: MOUNJARO — 4 pens every 28 days
    ProductMOUNJARO (tirzepatide) pens
    Quantity4 pens every 28 days
    RequirementPA and QL indicated in listing
    inv-217: Accu-Chek / OneTouch blood glucose test strips — 150
    ProductAccu‑Chek / OneTouch blood glucose test strips
    Quantity150 test strips every 30 days
    Coverage noteOTC; QL specified
    inv-218: Dexcom G6/G7 sensors — 3
    ProductDexcom G6 / G7 sensors
    Quantity3 sensors every 30 days
    Coverage noteQL specified for sensors in listing
    inv-232: folic acid 800mcg (caps) — 100
    ProductFolic acid 800 mcg (caps)
    Quantity100 caps every 30 days
    Coverage noteOTC; $0 copay for members 55 and younger capable of pregnancy; otherwise not covered

    Where Drugs Must Be Dispensed / Administered

    Note
    Note
    Note

    Background and Definitions

    The formulary groups drugs by clinical condition (for example, antineoplastic agents, analgesics, anti‑infectives, endocrine agents) and lists generic equivalents where available. Coverage is reported as a formulary tier with any applicable utilization controls (Prior Authorization, Step Therapy, Quantity Limits) shown on each product line; generic or preferred agents are emphasized as first‑line options to manage safety and cost.

    inv-108: generic — Generic drug
    TermGeneric
    DefinitionGeneric drug
    NoteGeneric drugs are FDA‑approved equivalents to brand drugs and are generally added to the formulary when available
    inv-109: prior authorization — Prior Authorization (PA)
    TermPrior Authorization
    AbbreviationPA
    DefinitionAdministrative approval required from CommunityCare ACA before coverage of specified products or strengths
    inv-110: ST — Step therapy (ST) — a requirement noted on many products indicating an authorization pathway or prior trial of other therapies may be req...
    TermStep therapy
    AbbreviationST
    DefinitionStep therapy (ST) — requirement to try preferred agent(s) first before a non‑preferred therapy will be covered
    inv-110: QL — Quantity Limit (QL) — maximum quantity allowed in the specified time period (e.g., tabs every 30 days).
    TermQuantity Limit
    AbbreviationQL
    DefinitionQuantity Limit (QL) — maximum quantity allowed in the specified time period (e.g., tabs every 30 days).
    inv-124: OTC — Over the counter (notation used for some products to indicate OTC availability).
    TermOTC
    DefinitionOver the counter (OTC) — notation used where product is available without prescription; some OTC items have QL or special copay rules
    ExampleAspirin EC adult low dose and folic acid entries are noted OTC with QL and special copay rules
    inv-127: Tier — Tier assignments indicate formulary placement (e.g., Tier 0, Tier 1, Tier 2, Tier 3).
    TermTier
    DefinitionTier — formulary placement indicating member cost‑sharing and coverage category (e.g., Tier 0–Tier 5)
    NoteTier assignments appear throughout product lines and influence PA/QL/step therapy expectations
    inv-125: Age-based copay exception — Certain bowel-prep products are listed as $0 copay for members aged 45 through 75; outside that age range alternate tier/coverage applies.
    PolicyAge‑based copay exception for selected bowel‑prep and folic acid products
    Example 1Selected bowel‑prep products (e.g., PLENVU, PEG‑Prep Kit) have $0 copay for members age 45–75; otherwise coverage differs
    Example 2Folic acid 800 mcg OTC: $0 copay for members 55 and younger capable of pregnancy; QL 100 caps every 30 days